0.7777

8.05% -0.0681

After Hours: .79 0.0123 +1.58%

Ginkgo Bioworks Holdings Inc (DNA)

Overview News Price History Option Chain Why DNA Down? Discussions Forecast

Ginkgo Bioworks Holdings Inc stock is currently priced at $0.7777, with a 24-hour trading volume of 72.55M. It has seen a -8.05% decreased in the last 24 hours and a -28.65% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.8525 pivot point. If it approaches the $0.7743 support level, significant changes may occur.

Previous Close:

$0.8458

Open:

$0.821

24h Volume:

72.55M

Market Cap:

$1.67B

Revenue:

$251.46M

Net Income/Loss:

$-892.87M

P/E Ratio:

-1.0954

EPS:

-0.71

Net Cash Flow:

$-336.30M

1W Performance:

-15.89%

1M Performance:

-28.65%

6M Performance:

-45.99%

1Y Performance:

-35.73%

1D Range:

$0.7403

$0.821

52W Range:

$0.7403

$2.545

Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile

Name

Ginkgo Bioworks Holdings Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

877 422 5362

Address

27 Drydock Avenue, 8th Floor, Boston

Employee

495

Twitter

Next Earnings Date

2024-02-29

Latest SEC Filings

DNA's Discussions on Twitter

Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-14-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-09-23	Downgrade	BTIG Research	Buy → Neutral
Jun-02-23	Downgrade	Goldman	Neutral → Sell
May-11-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-29-22	Initiated	Berenberg	Buy
Oct-04-22	Initiated	Morgan Stanley	Equal-Weight
May-18-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-02-22	Resumed	Cowen	Outperform
Feb-23-22	Initiated	Goldman	Neutral
Feb-01-22	Initiated	BofA Securities	Neutral
Jan-28-22	Initiated	BofA Securities	Buy
Jan-07-22	Initiated	BTIG Research	Buy
Nov-29-21	Initiated	Jefferies	Buy
Oct-13-21	Initiated	Raymond James	Outperform
Oct-12-21	Initiated	William Blair	Outperform
Sep-20-21	Initiated	HSBC Securities	Buy

View All

Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update

Seeking Alpha

Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.

The Motley Fool

Bull Market and Beyond: 3 Stocks Just Waiting to Soar

The Motley Fool

The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation

The Motley Fool

2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?

The Motley Fool

Sizing Your Penny Stocks Position, 3 Tips

PennyStocks

Ginkgo Bioworks Holdings Inc Stock (DNA) Financials Data

Ginkgo Bioworks Holdings Inc (DNA) Revenue 2024

DNA reported a revenue (TTM) of $251.46 million for the quarter ending December 31, 2023, a -47.36% decline year-over-year.

Ginkgo Bioworks Holdings Inc (DNA) Net Income 2024

DNA net income (TTM) was -$892.87 million for the quarter ending December 31, 2023, a +57.58% increase year-over-year.

Ginkgo Bioworks Holdings Inc (DNA) Cash Flow 2024

DNA recorded a free cash flow (TTM) of -$336.30 million for the quarter ending December 31, 2023, a -10.45% decrease year-over-year.

Ginkgo Bioworks Holdings Inc (DNA) Earnings per Share 2024

DNA earnings per share (TTM) was -$0.47 for the quarter ending December 31, 2023, a +63.57% growth year-over-year.

Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to advance treatments for orphan and rare diseases. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.